- Home
- ATYR vs SERV Comparison
ATYR vs SERV Comparison
Compare ATYR & SERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SERV
- Stock Information
- Founded
- ATYR 2005
- SERV 2017
- Country
- ATYR United States
- SERV United States
- Employees
- ATYR 59
- SERV N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SERV Industrial Specialties
- Sector
- ATYR Health Care
- SERV Consumer Discretionary
- Exchange
- ATYR Nasdaq
- SERV Nasdaq
- Market Cap
- ATYR 105.8M
- SERV 609.5M
- IPO Year
- ATYR 2015
- SERV N/A
- Fundamental
- Price
- ATYR $1.03
- SERV $11.73
- Analyst Decision
- ATYR Buy
- SERV Buy
- Analyst Count
- ATYR 6
- SERV 5
- Target Price
- ATYR $8.88
- SERV $17.75
- AVG Volume (30 Days)
- ATYR 15.6M
- SERV 8.0M
- Earning Date
- ATYR 11-06-2025
- SERV 11-06-2025
- Dividend Yield
- ATYR N/A
- SERV N/A
- EPS Growth
- ATYR N/A
- SERV N/A
- EPS
- ATYR N/A
- SERV N/A
- Revenue
- ATYR N/A
- SERV $1,479,483.00
- Revenue This Year
- ATYR $420.85
- SERV $133.00
- Revenue Next Year
- ATYR $1,919.44
- SERV $795.71
- P/E Ratio
- ATYR N/A
- SERV N/A
- Revenue Growth
- ATYR N/A
- SERV N/A
- 52 Week Low
- ATYR $0.97
- SERV $4.66
- 52 Week High
- ATYR $7.29
- SERV $24.35
- Technical
- Relative Strength Index (RSI)
- ATYR 22.25
- SERV 58.89
- Support Level
- ATYR $1.00
- SERV $10.13
- Resistance Level
- ATYR $6.50
- SERV $13.12
- Average True Range (ATR)
- ATYR 0.46
- SERV 0.81
- MACD
- ATYR -0.51
- SERV 0.20
- Stochastic Oscillator
- ATYR 1.01
- SERV 60.84
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.